Skip to main content

Concizumab May Be Effective Prophylaxis for Hemophilia A or B With Inhibitors

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

FRIDAY, Sept. 1, 2023 -- Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of Medicine.

Tadashi Matsushita, M.D., Ph.D., from Nagoya University Hospital in Japan, and colleagues evaluated the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. As part of the explorer7 phase 3 trial, participants were randomly assigned to receive no prophylaxis for at least 24 weeks (group 1; 19 patients) or to receive concizumab prophylaxis for at least 32 weeks (group 2; 33 patients), or they were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4; 81 patients).

The researchers found that the estimated mean annualized bleeding rate in group 1 was 11.8 episodes versus 1.7 episodes in group 2 (rate ratio, 0.14; P < 0.001). For patients receiving concizumab (groups 2, 3, and 4), the overall median annualized bleeding rate was zero episodes. After concizumab therapy was restarted, no thromboembolic events were reported. Plasma concentrations of concizumab were stable over time.

“Concizumab represents a novel, subcutaneous treatment option in patients with hemophilia A or B with inhibitors that can potentially improve long-term outcomes,” the authors write.

The study was funded by Novo Nordisk.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Disparities in Direct Oral Anticoagulant Initiation Have Declined in Recent Years

FRIDAY, May 10, 2024 -- Historical disparities in initiation of direct oral anticoagulants (DOACs) for atrial fibrillation have lessened for Black and Hispanic patients, according...

Earlier Receipt of Whole Blood Transfusion Improves Survival

WEDNESDAY, Feb. 7, 2024 -- For patients presenting with severe hemorrhage, receipt of whole blood (WB) transfusion earlier within the first 24 hours of emergency department...

Little Change Seen in Rates of ED Discharge After Acute Pulmonary Embolism

MONDAY, Jan. 29, 2024 -- For patients with acute pulmonary embolism (PE), the rates of discharge from the emergency department were stable between 2012 and 2020, according to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.